The US Food and Drug Administration (FDA) has cleared Biotronik's new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds).

Lumax 740 helps physicians to monitor, manage and treat patients’ heart failure progression and arrhythmias.

Lumax 740 also facilitates physicians to reduce the chances of patients receiving an inappropriate shock as confirmed by the ECOST1 study and is durable with extended longevity.

Lumax 740 devices utilize the company’s thoracic impedance(TI) feature to measure TI , which has been shown to inversely correlate with lung fluid.

Lumax 740 devices integrate the company’s Home Monitoring which helps physician to use the TI information as additional insight to manage important aspects of patient care including drugs used to adjust fluid levels.